Mylan is a popular generic & specialty pharmaceuticals brand having its global headquarters in Canonsburg, Pennsylvania.
Additionally, the company has executive offices in Hertfordshire, United Kingdom whereas it is registered in the Netherlands.
Mylan Pharmaceuticals was established by Milan Puskar & Don Panoz in 1961 in West Virginia, United States.
As of 2015 records, the net income of the company was US$ 4.216 billion, whereas their total assets in the same year were US$ 22.267 billion. There are more than 35,000 people employed by the company across the world.
Mylan Pharmaceuticals Operations
The company controls its operations through a great variety of subsidiaries that include Mylan Pharmaceuticals ULC, Mylan Laboratories Limited, Somerset Pharmaceuticals, Mylan Technologies, Mylan New Zealand Limited, Mulan Seiyaku Limited, & Mylan Seiyaku Limited.
Additionally, they have some European divisions that are named as Generics Pharma Hellas, Qualimed, Docpharma, Acrana Arzenimttel, & Gerald Laboratories.
Mylan Pharmaceuticals Important Details
The company trade on the New York Stock Exchange under the name MYL. They also have an active listing on the Tel Aviv Stock Exchange.
Additionally, they are an active member of NASDAQ Biotechnology, NASDAQ 100, and S&P.
The major products sell by the company are active pharmaceuticals ingredients, generic and specialty pharmaceuticals.
The Chief Executive Officer of the company is Heather Bresch.
They are the world’s second-biggest generic & specialty Pharmaceuticals Company. It has acquired many companies since its foundation.
It includes names like Matrix Laboratories Limited, Merck KGaA, &Abbott Laboratories among others.
All these acquisitions help the company to become such a big brand. They control all their operations under Dutch law.